A survey suggests that migraineurs, particularly patients with chronic migraine, have unmet acute treatment needs.
LOS ANGELES—Migraine treatment regimens fall short of providing rapid and consistent relief, restoring patients’ ability to function, and reducing the risk of migraine recurrence, according to research presented at the 54th Annual Scientific Meeting of the American Headache Society.
Many patients taking prescription drugs for migraine are not getting the optimal benefits from their treatment, said Richard Lipton, MD, Lowe Professor and Vice Chair of Neurology at the Albert Einstein College of Medicine in Bronx, New York. Furthermore, treatment optimization was better for patients with episodic migraine than for patients with chronic migraine, as measured by the Migraine Treatment Optimization Questionnaire-5 (M-TOQ-5). Higher scores on the questionnaire reflect better treatment.
The mean M-TOQ-5 score for episodic migraine (4.01) was approximately 0.5 SD higher than that for chronic migraine (3.25). The difference between the two scaled optimization mean scores remained significant after the researchers adjusted the data for potentially confounding factors such as age and gender.